Main patient characteristics
| Parameter . | Value . |
|---|---|
| Number of patients* | 24 |
| Age, median y (range) | 52 (28-69) |
| Histologic subtype, no. patients (%) | |
| PTCL-U | 14 (58.3) |
| AILD-T | 6 (25.0) |
| ALC-Alk− | 3 (12.5) |
| EATCL | 1 (4.2) |
| Ann Arbor stage III = IV, no. patients (%) | |
| III-IV | 21 (87.5) |
| B symptoms, no. patients (%) | 11 (45.8) |
| Bone marrow involvement, no. patients (%) | 10 (41.7) |
| Elevated LDH serum level, no. patients (%) | 12 (50.0) |
| IPI score, no. patients (%) | |
| 0-1 | 8 (33.3) |
| 2-3 | 14 (58.3) |
| 4-5 | 2 (8.3) |
| Parameter . | Value . |
|---|---|
| Number of patients* | 24 |
| Age, median y (range) | 52 (28-69) |
| Histologic subtype, no. patients (%) | |
| PTCL-U | 14 (58.3) |
| AILD-T | 6 (25.0) |
| ALC-Alk− | 3 (12.5) |
| EATCL | 1 (4.2) |
| Ann Arbor stage III = IV, no. patients (%) | |
| III-IV | 21 (87.5) |
| B symptoms, no. patients (%) | 11 (45.8) |
| Bone marrow involvement, no. patients (%) | 10 (41.7) |
| Elevated LDH serum level, no. patients (%) | 12 (50.0) |
| IPI score, no. patients (%) | |
| 0-1 | 8 (33.3) |
| 2-3 | 14 (58.3) |
| 4-5 | 2 (8.3) |
A total of 25 patients entered the study program and were evaluable for treatment feasibility and toxicity; however, 1 patient had a revised diagnosis of lymphoblastic lymphoma and was excluded from the response analysis.